Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer.

Date publication

janvier 2020

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HARLE Alexandre , Pr MERLIN Jean-Louis , Dr GILSON Pauline , Dr GAVOILLE Céline , Dr LAMBERT Aurélien

Tous les auteurs :
Franczak C, Witz A, Geoffroy K, Demange J, Rouyer M, Husson M, Massard V, Gavoille C, Lambert A, Gilson P, Gambier N, Scala-Bertola J, Merlin JL, Harlé A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31940389

Résumé

Cell-free DNA detection is becoming a surrogate assay for tumor genotyping. Biological fluids often content a very low amount of cell-free tumor DNA and assays able to detect very low allele frequency mutant with a few quantities of DNA are required. We evaluated the ability of the fully-automated molecular diagnostics platform Idylla for the detection of KRAS, NRAS and BRAF hotspot mutations in plasma from patients with metastatic colorectal cancer (mCRC).

Référence

PLoS ONE. 2020 ;15(1):e0227294